IVB injections successful for mCNV

Article

Intravitreal bevacizumab (IVB) provide sustained and effective treatment for myopic choroidal neovascularization (mCNV).

Intravitreal bevacizumab (IVB) provide sustained and effective treatment for myopic choroidal neovascularization (mCNV).

The prospective case series, led by Dr Magda Gharbiya, Department of Ophthalmology, Sapienza University – Umberto I Hospital, Rome, Italy, consisted of 32 eyes of 30 mCNV patients.

Each participant was administered three monthly 1.25 mg IVB injections. Regression analysis was used to measure the prognostic factors of age, axial length, baseline BCVA, pre-treatment CNV area, CNV location and peripapillary atrophy area. Best-corrected visual acuity (BCVA) and CNV area were compared pre-treatment and post-treatment.

In 32 eyes the results were evaluated at two years and in 27 eyes they were evaluated at three years. Mean baseline BCVA significantly improved from 30.1 letters to 45.4 letters at three years. The outcome was better in eyes with juxtafoveal CNV.

A positive correlation was found between baseline BCVA and final BCVA, but there was a negative correlation for age. CNV area was reduced from 0.63 mm2 at baseline to 0.40 mm2 at the three-year follow-up. Peripapillary atrophy area was the sole contributing factor affecting the need for re-treatment.

The factors that independently correlated with the BCVA outcome were initial BCVA and age. Three monthly injections of IVB provide effective and sustained results for mCNV treatment.

The abstract can be found in the British Journal of Ophthalmology.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.